Pharvaris B.V.

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

Pharvaris NV is seeking to improve upon the standard-of-care for both treatment and prevention of hereditary angioedema (HAE) with its oral bradykinin B2 receptor antagonist deucrictibant, announcing

About 15 months after ending development of a different hereditary angioedema candidate due to liver safety worries, KalVista Pharmaceuticals, Inc. reported what analysts called best-case scenario r

Recent private placements and follow-on financings show that despite public company valuations being down across the board during the past two years, it still is possible to drum up investor support f